Tubo-ovarian abscess
Last reviewed: May 2026
Outline
Tubo-ovarian abscess is a polymicrobial inflammatory collection involving the fallopian tube, ovary, or both, most commonly arising as a complication of pelvic inflammatory disease (PID). It occurs in 10–30% of hospitalized PID patients and carries significant morbidity (infertility, chronic pelvic pain, ectopic pregnancy) and potential mortality from rupture and sepsis. [1-2]
1. History
- Chief complaint: Lower abdominal/pelvic pain — the predominant symptom; often progressive and bilateral
- Symptom characterization: Dull, constant pelvic pain; may be unilateral or bilateral; worsened by movement or intercourse
- Timing/triggers: Indolent onset over days; may follow menses, recent IUD insertion, or gynecologic procedure [3]
- Associated symptoms: Fever (present in ~50–88%), nausea/vomiting (~50%), abnormal vaginal discharge, dyspareunia, irregular bleeding, diarrhea [2][4]
- Important negatives: Only a minority present with vaginal symptoms; absence of fever does not exclude TOA [2]
- Key pearl: The triad of fever + leukocytosis + diarrhea should raise suspicion for TOA over uncomplicated PID [4]
2. Alarm Features
- Hemodynamic instability (tachycardia, hypotension) — suggests rupture or sepsis
- Peritoneal signs (rebound, rigidity, guarding) — concerning for ruptured TOA, a surgical emergency
- Rapidly worsening pain with acute deterioration
- High fever (>38.5°C) with signs of systemic toxicity
- Bilateral large abscesses — higher failure rate with antibiotics alone [2][5]
- Postmenopausal TOA — must rule out underlying malignancy [1]
3. Medications
Relevant contributors:
- IUD use (modest risk, primarily in first 3 weeks after insertion)
- Immunosuppressive medications
Treatment — CDC-recommended parenteral regimens: [6]
- First-line: Ceftriaxone 1 g IV q24h + doxycycline 100 mg PO/IV q12h + metronidazole 500 mg PO/IV q12h
- Alternative: Cefotetan 2 g IV q12h + doxycycline 100 mg PO/IV q12h
- Alternative: Cefoxitin 2 g IV q6h + doxycycline 100 mg PO/IV q12h
- For TOA specifically: Clindamycin 900 mg IV q8h + gentamicin (loading 2 mg/kg then 1.5 mg/kg q8h) — provides enhanced anaerobic coverage [6-7]
- Alternative: Ampicillin-sulbactam 3 g IV q6h + doxycycline 100 mg PO/IV q12h — effective against TOA pathogens [6]
Step-down oral therapy: Doxycycline 100 mg BID + metronidazole 500 mg BID (or clindamycin 450 mg QID) to complete 14 days total [6]
Contraindications/cautions:
- Doxycycline: avoid IV if possible due to infusion pain; oral bioavailability is equivalent [6]
- IUD removal is generally not recommended during acute treatment — does not hasten resolution and may delay it [7]
4. Diet
- NPO if surgical intervention is anticipated or if hemodynamically unstable
- Adequate hydration is essential during acute illness
- No specific long-term dietary modifications
5. Review of Systems
- GI: Nausea, vomiting, diarrhea (diarrhea is a distinguishing feature of TOA vs. uncomplicated PID) [4]
- GU: Dysuria, urinary frequency (may mimic UTI), vaginal discharge, abnormal bleeding
- Constitutional: Fever, chills, malaise, anorexia
- Musculoskeletal: Back pain
- RUQ pain: Consider Fitz-Hugh–Curtis syndrome (perihepatitis) [8]
6. Collateral History and Family History
- Sexual history: Number of partners, new partners, condom use, history of STIs
- Gynecologic history: Prior PID episodes, recent IUD placement, recent uterine instrumentation (D&C, HSG, endometrial biopsy)
- Social context: Barriers to follow-up, access to medications
- Important: TOA can occur in non-sexually active patients (especially adolescents) — often from GI flora; do not dismiss the diagnosis based on sexual history alone [9]
- Family history: Not a major contributor, though immunodeficiency states may be hereditary
7. Risk Factors
- History of PID (strongest risk factor)
- Multiple sexual partners
- IUD use (especially recent insertion) [1]
- Recent gynecologic instrumentation (D&C, hysteroscopy, embryo transfer)
- Diabetes mellitus [2]
- Immunosuppression (HIV, transplant, chronic steroids) [1]
- Older age and higher BMI — associated with antibiotic treatment failure [5][10]
- GI source — TOA can arise from appendicitis, diverticulitis, or Crohn's disease [2]
8. Differential Diagnosis
- Ectopic pregnancy — always rule out with β-hCG in reproductive-age women
- Ovarian torsion — acute unilateral pain, often with nausea/vomiting; Doppler US critical
- Appendicitis — RLQ pain; CT can differentiate (right ovarian vein entering a pelvic abscess has 100% specificity for TOA vs. peri-appendiceal abscess) [11]
- Ruptured ovarian cyst — acute onset, often mid-cycle; free fluid on US
- Diverticular abscess — older patients, LLQ pain, CT distinguishes
- Endometrioma — chronic dysmenorrhea, "chocolate cyst" on imaging
- Ovarian malignancy — especially in postmenopausal patients with adnexal mass [3]
- Uncomplicated PID — no discrete abscess on imaging; management differs significantly [12]
9. Past Medical History
- Prior PID or TOA (recurrence risk is significant)
- Prior ectopic pregnancy
- History of STIs (chlamydia, gonorrhea)
- Abdominal/pelvic surgery
- Chronic illnesses: diabetes, HIV, IBD
- Immunosuppressive conditions
10. Physical Exam
Vital signs:
- Fever (>38°C in ~50–88% of cases) [2][4]
- Tachycardia; hypotension if ruptured/septic
Abdominal exam:
- Lower abdominal tenderness (bilateral > unilateral)
- Guarding — independent predictor of need for surgery [13]
- Rebound tenderness — suggests peritonitis/rupture
Pelvic exam:
- Cervical motion tenderness (chandelier sign)
- Adnexal tenderness and/or palpable adnexal mass
- Purulent cervical/vaginal discharge
- Uterine tenderness
Pearl: Physical exam alone has limited sensitivity — a palpable mass is found in only ~50% of cases; imaging is required for definitive diagnosis [2]
11. Lab Studies
Recommended:
- CBC with differential — leukocytosis (WBC often >15,000; mean ~21,800 in TOA vs. ~14,900 in PID alone) [4]
- CRP — the strongest laboratory predictor of TOA; >49.3 mg/L suggests TOA (sensitivity 85%, specificity 93%); serial CRP trending is valuable for monitoring treatment response [14-15]
- ESR — elevated but less specific than CRP
- β-hCG — mandatory to rule out ectopic pregnancy
- Gonorrhea/chlamydia NAAT (cervical or urine)
- Blood cultures — if febrile or septic
- BMP, hepatic panel — baseline for antibiotic dosing and monitoring
- Urinalysis — to exclude UTI/pyelonephritis
- Lactate — if sepsis suspected
- HIV testing — per CDC STI guidelines
Expected abnormalities: Elevated WBC, CRP, ESR; left shift on differential
12. Imaging
First-line: Transvaginal ultrasound (TVUS) [11-12][16]
- Sensitivity 56–93%, specificity 86–98% for TOA
- Findings: complex adnexal mass with varying echogenicity, debris, septations, irregular margins, loss of normal ovarian/tubal boundaries, pyosalpinx, cul-de-sac fluid with internal echoes [11]
CT abdomen/pelvis with IV contrast: [11][17]
- Higher sensitivity than US (100% in one study); better for differentiating GI pathology
- Findings: thick-walled adnexal fluid collection, septations, indistinct borders with adjacent bowel, gas bubbles within the mass (highly specific)
- Useful when US is inconclusive or GI source is suspected
MRI: Best soft-tissue resolution; useful when US and CT are nondiagnostic, especially in pregnant patients [16]
When imaging is unnecessary: Imaging is always required — clinical diagnosis alone is insufficient for TOA [1]
13. Special Tests
Scoring systems:
- Yongue score — uses temperature, CRP, and abscess diameter to predict antibiotic failure (score ≥4 predicts need for intervention; sensitivity 69%, specificity 88%). However, external validation has shown poor discriminatory ability [5][13][18]
- CRP trending — rising CRP over days 1–2 of treatment predicts need for invasive intervention; a <37.1% decrease in CRP by day 4 suggests treatment failure [14-15]
Point-of-care tests:
- Bedside POCUS (transvaginal) — can expedite identification of TOA in the ED [12]
- Wet prep of vaginal discharge
Procedures:
- Image-guided percutaneous drainage (CT- or US-guided) — for abscesses >3 cm failing antibiotics [19]
- Posterior colpotomy drainage — transvaginal approach for cul-de-sac collections
14. ECG
- ECG is not routinely indicated unless:
- Sepsis with hemodynamic instability (evaluate for sepsis-related cardiac dysfunction)
- Pre-operative evaluation
- Tachycardia out of proportion to clinical picture
15. Assessment
Clinical summary: TOA is a high-risk, low-prevalence emergency diagnosis that complicates 10–30% of PID cases. Presentation is often nonspecific — predominantly lower abdominal pain with variable systemic symptoms. Approximately 75% respond to antibiotics alone, but ~25–35% require surgical or interventional drainage. [5][20]
Severity stratification:
- Mild: Small (<5 cm), unilateral, hemodynamically stable, low CRP
- Moderate: 5–8 cm, febrile, elevated CRP (>150 mg/L)
- Severe: >8 cm, bilateral, peritoneal signs, sepsis, or ruptured
Atypical presentations:
- Non-sexually active adolescents (GI flora-driven) [9]
- Postmenopausal women (must exclude malignancy) [1]
- GI-source TOA (appendicitis, diverticulitis) [2]
Complications: Rupture with peritonitis/sepsis (mortality up to 5–10%), infertility, ectopic pregnancy, chronic pelvic pain, recurrence, venous thromboembolism [1]
16. Treatment Plan
Initial stabilization:
- IV access, fluid resuscitation if septic
- Analgesia (NSAIDs ± opioids; NSAIDs do not improve PID outcomes but provide symptomatic relief) [7]
- NPO if surgical intervention anticipated
Antibiotics (start immediately — do not delay for imaging): [6]
- Primary: Ceftriaxone 1 g IV q24h + doxycycline 100 mg PO q12h + metronidazole 500 mg IV/PO q12h
- TOA-specific alternative: Clindamycin 900 mg IV q8h + gentamicin (loading + maintenance) — preferred by some for enhanced anaerobic coverage [7]
- Step-down: After 24–48 hours of clinical improvement → oral doxycycline + metronidazole (or clindamycin) to complete 14 days
Interventional/surgical management:
- Image-guided drainage (CT- or US-guided): for abscesses >3 cm not responding to 48–72 hours of antibiotics; high success rates with lower morbidity than surgery [15][19]
- Laparoscopy: Adhesiolysis, drainage, washout — fertility-sparing
- Laparotomy with salpingo-oophorectomy or TAH/BSO: Reserved for ruptured TOA, failed minimally invasive approaches, or postmenopausal patients [1][8]
Predictors of antibiotic failure (consider early intervention): abscess >6.25 cm, CRP >143.5 mg/L, age >41.5, BMI >26.7, bilateral abscesses, rising CRP on serial monitoring [5][10][14]
17. Disposition
Admission criteria (all TOA patients require admission):
- TOA is an indication for hospitalization per CDC guidelines [6-7]
- 24 hours of inpatient observation is recommended [6]
- IV antibiotics with close monitoring
Observation indications:
Specialist consultation triggers:
- OB/GYN: All cases — for co-management and potential surgical planning
- Interventional radiology: For image-guided drainage when antibiotics fail or large abscess at presentation
- Surgery/general surgery: If GI source suspected (appendiceal or diverticular abscess)
- ICU: Sepsis, hemodynamic instability, ruptured TOA
Discharge criteria:
- Afebrile for 24–48 hours
- Tolerating oral medications
- Improving pain and inflammatory markers (CRP trending down)
- Reliable follow-up arranged
18. Follow Up / Return Precautions
Follow-up timing:
- 48–72 hours after discharge for clinical reassessment
- 2–4 weeks: Repeat imaging (TVUS) to confirm resolution [9]
- STI testing for partners; treat all sexual contacts from the prior 60 days
Symptoms requiring immediate return:
- Worsening abdominal pain or new peritoneal signs
- Fever >38.3°C
- Inability to tolerate oral medications
- Syncope, dizziness, or signs of hemodynamic compromise
Patient counseling:
- Complete the full 14-day antibiotic course
- Abstain from intercourse until treatment is complete and symptoms resolve
- Discuss long-term fertility implications — TOA increases risk of infertility and ectopic pregnancy [1]
- Barrier contraception counseling to reduce future PID/TOA risk
Expected recovery: Clinical improvement typically within 48–72 hours of IV antibiotics. Complete radiologic resolution may take 2–4 weeks. Recurrence risk is significant, and some patients require multiple admissions. [5][9]
References
- 1.Boyens H, Bofill Rodriguez M, Wimsett J, et al. Interventions in Addition to Broad-Spectrum Intravenous Antibiotic Therapy for the Treatment of Radiologically Proven Tubo-Ovarian Abscess. The Cochrane Database of Systematic Reviews. 2025. Link
- 2.Boyens H, Bofill Rodriguez M, Wimsett J, et al. Interventions in Addition to Broad-Spectrum Intravenous Antibiotic Therapy for the Treatment of Radiologically Proven Tubo-Ovarian Abscess. The Cochrane Database of Systematic Reviews. 2025. Link
- 3.Boyens H, Bofill Rodriguez M, Wimsett J, et al. Interventions in Addition to Broad-Spectrum Intravenous Antibiotic Therapy for the Treatment of Radiologically Proven Tubo-Ovarian Abscess. The Cochrane Database of Systematic Reviews. 2025. Link
- 4.Bridwell RE, Koyfman A, Long B. High Risk and Low Prevalence Diseases: Tubo-Ovarian Abscess. The American Journal of Emergency Medicine. 2022. Link
- 5.Bridwell RE, Koyfman A, Long B. High Risk and Low Prevalence Diseases: Tubo-Ovarian Abscess. The American Journal of Emergency Medicine. 2022. Link
- 6.Committee on Practice Bulletins—Gynecology Practice Bulletin No. 174: Evaluation and Management of Adnexal Masses. Obstetrics and Gynecology. 2016. Link
- 7.Committee on Practice Bulletins—Gynecology Practice Bulletin No. 174: Evaluation and Management of Adnexal Masses. Obstetrics and Gynecology. 2016. Link
- 8.Sordia-Hernández LH, Serrano Castro LG, Sordia-Piñeyro MO, et al. Comparative Study of the Clinical Features of Patients With a Tubo-Ovarian Abscess and Patients With Severe Pelvic Inflammatory Disease. International Journal of Gynaecology and Obstetrics: The Official Organ of the International Federation of Gynaecology and Obstetrics. 2016. Link
- 9.Sordia-Hernández LH, Serrano Castro LG, Sordia-Piñeyro MO, et al. Comparative Study of the Clinical Features of Patients With a Tubo-Ovarian Abscess and Patients With Severe Pelvic Inflammatory Disease. International Journal of Gynaecology and Obstetrics: The Official Organ of the International Federation of Gynaecology and Obstetrics. 2016. Link
- 10.Marshall A, Wimsett J, Handforth C, et al. The Tubo-Ovarian Abscess Study (TOAST): A Single-Center Retrospective Review of Predictors of Failed Medical Management. International Journal of Gynaecology and Obstetrics: The Official Organ of the International Federation of Gynaecology and Obstetrics. 2025. Link
- 11.Marshall A, Wimsett J, Handforth C, et al. The Tubo-Ovarian Abscess Study (TOAST): A Single-Center Retrospective Review of Predictors of Failed Medical Management. International Journal of Gynaecology and Obstetrics: The Official Organ of the International Federation of Gynaecology and Obstetrics. 2025. Link
- 12.Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports. 2021. Link
- 13.Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports. 2021. Link
- 14.Brunham RC, Gottlieb SL, Paavonen J. Pelvic Inflammatory Disease. The New England Journal of Medicine. 2015. Link
- 15.Brunham RC, Gottlieb SL, Paavonen J. Pelvic Inflammatory Disease. The New England Journal of Medicine. 2015. Link
- 16.Sartelli M, Chichom-Mefire A, Labricciosa FM, et al. The Management of Intra-Abdominal Infections From a Global Perspective: 2017 WSES Guidelines for Management of Intra-Abdominal Infections. World Journal of Emergency Surgery : WJES. 2017. Link
- 17.Sartelli M, Chichom-Mefire A, Labricciosa FM, et al. The Management of Intra-Abdominal Infections From a Global Perspective: 2017 WSES Guidelines for Management of Intra-Abdominal Infections. World Journal of Emergency Surgery : WJES. 2017. Link
- 18.Fei YF, Lawrence AE, McCracken KA. Tubo-Ovarian Abscess in Non-Sexually Active Adolescent Girls: A Case Series and Literature Review. Journal of Pediatric and Adolescent Gynecology. 2021. Link
- 19.Fei YF, Lawrence AE, McCracken KA. Tubo-Ovarian Abscess in Non-Sexually Active Adolescent Girls: A Case Series and Literature Review. Journal of Pediatric and Adolescent Gynecology. 2021. Link
- 20.Akselim B, Karaşin SS, Demirci A, Üstünyurt E. Can Antibiotic Treatment Failure in Tubo-Ovarian Abscess Be Predictable?. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2021. Link
- 21.Akselim B, Karaşin SS, Demirci A, Üstünyurt E. Can Antibiotic Treatment Failure in Tubo-Ovarian Abscess Be Predictable?. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2021. Link
- 22.Brook OR, Dadour JR, Robbins JB, et al. ACR Appropriateness Criteria® Acute Pelvic Pain in the Reproductive Age Group: 2023 Update. Journal of the American College of Radiology : JACR. 2024. Link
- 23.Brook OR, Dadour JR, Robbins JB, et al. ACR Appropriateness Criteria® Acute Pelvic Pain in the Reproductive Age Group: 2023 Update. Journal of the American College of Radiology : JACR. 2024. Link
- 24.Ultrasound Guidelines: Emergency, Point-of-Care, and Clinical Ultrasound Guidelines in Medicine. American College of Emergency Physicians (2023). 2023. Link
- 25.Ultrasound Guidelines: Emergency, Point-of-Care, and Clinical Ultrasound Guidelines in Medicine. American College of Emergency Physicians (2023). 2023. Link
- 26.Baer A, Lia M, Weisgerber C, Aktas B, Wolf B. Predicting the Need for Surgery in Tubo-Ovarian Abscess: A Clinical Evaluation and External Validation of Risk Scores. Journal of Minimally Invasive Gynecology. 2026. Link
- 27.Baer A, Lia M, Weisgerber C, Aktas B, Wolf B. Predicting the Need for Surgery in Tubo-Ovarian Abscess: A Clinical Evaluation and External Validation of Risk Scores. Journal of Minimally Invasive Gynecology. 2026. Link
- 28.Ribak R, Schonman R, Sharvit M, et al. Can the Need for Invasive Intervention in Tubo-Ovarian Abscess Be Predicted? The Implication of C-Reactive Protein Measurements. Journal of Minimally Invasive Gynecology. 2020. Link
- 29.Ribak R, Schonman R, Sharvit M, et al. Can the Need for Invasive Intervention in Tubo-Ovarian Abscess Be Predicted? The Implication of C-Reactive Protein Measurements. Journal of Minimally Invasive Gynecology. 2020. Link
- 30.Türen Demir E, Energin H, Kilic F. Image-Guided Drainage Management of Tubo-Ovarian Abscess and the Role of C-Reactive Protein Measurements in Monitoring Treatment Response: A Single-Center Experience. Archives of Gynecology and Obstetrics. 2023. Link
- 31.Türen Demir E, Energin H, Kilic F. Image-Guided Drainage Management of Tubo-Ovarian Abscess and the Role of C-Reactive Protein Measurements in Monitoring Treatment Response: A Single-Center Experience. Archives of Gynecology and Obstetrics. 2023. Link
- 32.Frasca DJ, Jarrio CE, Perdue J. Evaluation of Acute Pelvic Pain in Women. American Family Physician. 2023. Link
- 33.Frasca DJ, Jarrio CE, Perdue J. Evaluation of Acute Pelvic Pain in Women. American Family Physician. 2023. Link
- 34.Scheirey CD, Fowler KJ, Therrien JA, et al. ACR Appropriateness Criteria Acute Nonlocalized Abdominal Pain. Journal of the American College of Radiology : JACR. 2018. Link
- 35.Scheirey CD, Fowler KJ, Therrien JA, et al. ACR Appropriateness Criteria Acute Nonlocalized Abdominal Pain. Journal of the American College of Radiology : JACR. 2018. Link
- 36.Yongue G, Mollier J, Anin S, et al. Tubo-Ovarian Abscess: A Proposed New Scoring System to Guide Clinical Management. International Journal of Gynaecology and Obstetrics: The Official Organ of the International Federation of Gynaecology and Obstetrics. 2022. Link
- 37.Yongue G, Mollier J, Anin S, et al. Tubo-Ovarian Abscess: A Proposed New Scoring System to Guide Clinical Management. International Journal of Gynaecology and Obstetrics: The Official Organ of the International Federation of Gynaecology and Obstetrics. 2022. Link
- 38.Weiss CR, Bailey CR, Hohenwalter EJ, et al. ACR Appropriateness Criteria® Radiologic Management of Infected Fluid Collections. Journal of the American College of Radiology : JACR. 2020. Link
- 39.Weiss CR, Bailey CR, Hohenwalter EJ, et al. ACR Appropriateness Criteria® Radiologic Management of Infected Fluid Collections. Journal of the American College of Radiology : JACR. 2020. Link
- 40.Savaris RF, Fuhrich DG, Maissiat J, Duarte RV, Ross J. Antibiotic Therapy for Pelvic Inflammatory Disease. The Cochrane Database of Systematic Reviews. 2020. Link
- 41.Savaris RF, Fuhrich DG, Maissiat J, Duarte RV, Ross J. Antibiotic Therapy for Pelvic Inflammatory Disease. The Cochrane Database of Systematic Reviews. 2020. Link